menu

CME: Novel Interventions for Preventing/Reducing Pain Crisis in Sickle Cell Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Novel Interventions for Preventing & Reducing Pain Crisis in Sickle Cell Disease

close
0.50 credits
30 minutes
Novel Interventions for Preventing & Reducing Pain Crisis in Sickle Cell Disease
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Sickle cell disease (SCD) affects approximately 100,000 individuals in the United States. Vaso-occlusive crisis (VOC), characterized by the sudden onset of severe pain, is the most common reason for hospital visits in patients with SCD. However, despite the availability of guidelines on the recommended treatment, acute pain in SCD is often undertreated. Although opioids are recommended for severe acute pain episodes, the concern about addiction often results in clinicians failing to provide adequate pain control. Hydroxyurea is the only treatment that modifies the disease process in SCD; however, many providers are uncomfortable prescribing it, and many eligible patients with SCD remain inadequately treated.

    Now, new therapies are becoming available, and clinicians have a greater need for education about the efficacy and safety data of established and novel treatments for the management and prevention of VOCs.

    This activity will review the most recent clinical data and evidence-based updates and provide expert insights on preventing and reducing VOCs in sickle cell disease.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Examine acute and chronic complications associated with sickle cell disease (SCD)
    • Formulate optimal treatment plans for the management of SCD based on the efficacy and safety of newer and established, disease-specific therapies and current guideline recommendations
    • Formulate optimal treatment plans for acute pain management in patients with SCD presenting with a vaso-occlusive crisis (VOC)
    • Evaluate data on novel therapies for the prevention of VOC in patients with SCD and how they may be utilized in future management strategies
  • Target Audience

    This activity is intended for hematologists, emergency medical professionals, primary care physicians, advanced practitioners (defined as advance practice nurses, pharmacists, physician assistants), and other healthcare professionals involved in the treatment and management of sickle cell disease.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Julie Kanter, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Rockpointe; Medscape; and  PeerVoice. Serve(d) as a speaker or a member of a speakers bureau for: Terumo Pharmaceutical Solution, Novartis Pharmaceuticals Corp, and bluebird bio. Research grant: National Institutes of Health and Health Resources and Services Administration. Scientific advisory board: Novartis Pharmaceuticals Corp; Sangamo Therapeutics, Inc; and AstraZeneca Pharmaceuticals LP. Grant Review: Pfizer, Inc.

    Foluso "Joy" Ogunsile, MD, reported a financial interest/relationship or affiliation in the form of Other - travel, Novartis Pharmaceuticals Corporation.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: AXIS planners and managers, Jocelyn Timko, BS; Michael Brandt, PharmD, FASHP; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS reports her spouse has a financial interest/relationship or affiliation in the form of Common stock, Exelixis. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock, Merck.

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/17/2020. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-19-055-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer    
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Sickle cell disease (SCD) affects approximately 100,000 individuals in the United States. Vaso-occlusive crisis (VOC), characterized by the sudden onset of severe pain, is the most common reason for hospital visits in patients with SCD. However, despite the availability of guidelines on the recommended treatment, acute pain in SCD is often undertreated. Although opioids are recommended for severe acute pain episodes, the concern about addiction often results in clinicians failing to provide adequate pain control. Hydroxyurea is the only treatment that modifies the disease process in SCD; however, many providers are uncomfortable prescribing it, and many eligible patients with SCD remain inadequately treated.

    Now, new therapies are becoming available, and clinicians have a greater need for education about the efficacy and safety data of established and novel treatments for the management and prevention of VOCs.

    This activity will review the most recent clinical data and evidence-based updates and provide expert insights on preventing and reducing VOCs in sickle cell disease.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Examine acute and chronic complications associated with sickle cell disease (SCD)
    • Formulate optimal treatment plans for the management of SCD based on the efficacy and safety of newer and established, disease-specific therapies and current guideline recommendations
    • Formulate optimal treatment plans for acute pain management in patients with SCD presenting with a vaso-occlusive crisis (VOC)
    • Evaluate data on novel therapies for the prevention of VOC in patients with SCD and how they may be utilized in future management strategies
  • Target Audience

    This activity is intended for hematologists, emergency medical professionals, primary care physicians, advanced practitioners (defined as advance practice nurses, pharmacists, physician assistants), and other healthcare professionals involved in the treatment and management of sickle cell disease.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Julie Kanter, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Rockpointe; Medscape; and  PeerVoice. Serve(d) as a speaker or a member of a speakers bureau for: Terumo Pharmaceutical Solution, Novartis Pharmaceuticals Corp, and bluebird bio. Research grant: National Institutes of Health and Health Resources and Services Administration. Scientific advisory board: Novartis Pharmaceuticals Corp; Sangamo Therapeutics, Inc; and AstraZeneca Pharmaceuticals LP. Grant Review: Pfizer, Inc.

    Foluso "Joy" Ogunsile, MD, reported a financial interest/relationship or affiliation in the form of Other - travel, Novartis Pharmaceuticals Corporation.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: AXIS planners and managers, Jocelyn Timko, BS; Michael Brandt, PharmD, FASHP; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS reports her spouse has a financial interest/relationship or affiliation in the form of Common stock, Exelixis. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock, Merck.

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/17/2020. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-19-055-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer    
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/9/20